Filing Details
- Accession Number:
- 0001104659-19-007912
- Form Type:
- 13G Filing
- Publication Date:
- 2019-02-13 16:06:06
- Filed By:
- Roivant Sciences Ltd.
- Company:
- Myovant Sciences Ltd. (NYSE:MYOV)
- Filing Date:
- 2019-02-13
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | 38,341,357 | 0 | 38,341,357 | 0 | 38,341,357 | 54.1% |
|
| UNITED STATES |
|
|
| SECURITIES AND EXCHANGE COMMISSION |
|
|
| Washington, D.C. 20549 |
|
SCHEDULE 13G/A
INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934*
(Amendment No. 1)*
Myovant Sciences Ltd.
(Name of Issuer)
Common shares, $0.000017727 par value per share
(Title of Class of Securities)
G637AM102
(CUSIP Number)
December 31, 2018
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| o | Rule 13d-1(b) |
| o | Rule 13d-1(c) |
| x | Rule 13d-1(d) |
* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No.: G637AM102 | |||||
|
| |||||
|
| (1) | Names of Reporting Persons | |||
|
| |||||
|
| (2) | Check the Appropriate Box if a Member of a Group (See Instructions) | |||
|
|
| (a) | o | ||
|
|
| (b) | o | ||
|
| |||||
|
| (3) | SEC Use Only | |||
|
| |||||
|
| (4) | Citizenship or Place of Organization | |||
|
|
|
| |||
| Number of | (5) | Sole Voting Power | |||
|
| |||||
| (6) | Shared Voting Power | ||||
|
| |||||
| (7) | Sole Dispositive Power | ||||
|
| |||||
| (8) | Shared Dispositive Power | ||||
|
| |||||
|
| (9) | Aggregate Amount Beneficially Owned by Each Reporting Person | |||
|
| |||||
|
| (10) | Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o | |||
|
| |||||
|
| (11) | Percent of Class Represented by Amount in Row (9) | |||
|
| |||||
|
| (12) | Type of Reporting Person (See Instructions) | |||
(1) All share percentage calculations in this Schedule 13G/A are based on 70,812,541 common shares, $0.000017727 par value per share, of Myovant Sciences Ltd. (the Issuer) outstanding as of February 1, 2019, as reported on the Issuers quarterly report on Form 10-Q for the quarterly period ended December 31, 2018, filed with the Securities and Exchange Commission on February 7, 2019.
2
| Item 1(a). | Name of Issuer. The name of the issuer is Myovant Sciences Ltd. (the Issuer). | |
| Item 1(b). | Address of Issuers Principal Executive Offices. The Issuers principal executive offices are located at Suite 1, 3rd Floor, 11-12 St. Jamess Square, London SW1Y 4LB, United Kingdom. | |
| Item 2(a). | Name of Person Filing. | |
| Item 2(b). | Address of Principal Business Office or, if none, Residence. | |
| Item 2(c). | Citizenship. | |
| Item 2(d). | Title of Class of Securities. | |
| Item 2(e). | CUSIP No. | |
|
| ||
| Item 3. |
| |
| Not applicable. | ||
3
| Item 4. | Ownership. | ||
| Each Reporting Person: | |||
|
| (a) | Amount beneficially owned: 38,341,357 | |
|
| (b) | Percent of class: 54.1% | |
|
| (c) | Number of shares as to which the person has:
| |
|
|
| (i) | Sole power to vote or to direct the vote: 38,341,357 |
|
|
| (ii) | Shared power to vote or to direct the vote: 0 |
|
|
| (iii) | Sole power to dispose or to direct the disposition of: 38,341,357 |
|
|
| (iv) | Shared power to dispose or to direct the disposition of: 0 |
|
| |||
| Item 5. | Ownership of Five Percent or Less of a Class. | ||
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following: o | |||
|
| |||
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. | ||
| Not applicable. | |||
|
| |||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. | ||
| Not applicable. | |||
|
| |||
| Item 8. | Identification and Classification of Members of the Group. | ||
| Not applicable. | |||
|
| |||
| Item 9. | Notice of Dissolution of Group. | ||
| Not applicable. | |||
4
| Item 10. | Certification. |
| Not applicable. | |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
DATE: February 13, 2019
|
| ROIVANT SCIENCES LTD. | |
|
|
| |
|
|
| |
|
| By: | /s/ Marianne L. Romeo |
|
| Name: | Marianne L. Romeo |
|
| Title: | Authorized Signatory |
5